Blue Trust Inc. Sells 6,397 Shares of Sana Biotechnology, Inc. $SANA

Blue Trust Inc. trimmed its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 24.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,520 shares of the company’s stock after selling 6,397 shares during the quarter. Blue Trust Inc.’s holdings in Sana Biotechnology were worth $53,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Viewpoint Capital Management LLC raised its stake in shares of Sana Biotechnology by 19.1% during the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock valued at $77,000 after purchasing an additional 4,500 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Sana Biotechnology by 2.1% during the 1st quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock valued at $578,000 after purchasing an additional 7,230 shares during the period. Hsbc Holdings PLC raised its stake in shares of Sana Biotechnology by 26.5% during the 1st quarter. Hsbc Holdings PLC now owns 41,377 shares of the company’s stock valued at $65,000 after purchasing an additional 8,673 shares during the period. Rhumbline Advisers raised its stake in shares of Sana Biotechnology by 5.4% during the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock valued at $306,000 after purchasing an additional 9,359 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Sana Biotechnology by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company’s stock worth $1,791,000 after acquiring an additional 9,792 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Trading Down 5.1%

Shares of Sana Biotechnology stock opened at $5.03 on Friday. The firm has a market capitalization of $1.20 billion, a PE ratio of -4.75 and a beta of 1.91. The business’s 50-day moving average price is $3.55 and its 200-day moving average price is $2.99. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SANA. Morgan Stanley began coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Wedbush began coverage on Sana Biotechnology in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.